ORIGINAL ARTICLE

AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington’s disease

J Mniarikova1,2, V Zimmer3,4, R Martier1,2, CC Brouwers1, C Pythoud3,4, K Richetin3,4, M Rey3,4, J Lubelski1, MM Evers1, SJ van Deventer2, H Petry3, N Déglon3,4 and P Konstantinova1

Huntington’s disease (HD) is a fatal progressive neurodegenerative disorder caused by a mutation in the huntingtin (HTT) gene. To date, there is no treatment to halt or reverse the course of HD. Lowering of either total or only the mutant HTT expression is expected to have therapeutic benefit. This can be achieved by engineered micro (mi)RNAs targeting HTT transcripts and delivered by an adeno-associated viral (AAV) vector. We have previously showed a miHTT construct to induce total HTT knock-down in Hu128/21 HD mice, while miSNP50T and miSNP67T constructs induced allele-selective HTT knock-down in vitro. In the current preclinical study, the mechanistic efficacy and gene specificity of these selected constructs delivered by an AAV serotype 5 (AAV5) vector was addressed using an acute HD rat model. Our data demonstrated suppression of mutant HTT messenger RNA, which almost completely prevented mutant HTT aggregate formation, and ultimately resulted in suppression of DARPP-32-associated neuronal dysfunction. The AAV5-miHTT construct was found to be the most efficient, although AAV5-miSNP50T demonstrated the anticipated mutant HTT allele selectivity and no passenger strand expression. Ultimately, AAVS-delivered-miRNA-mediated HTT lowering did not cause activation of microglia or astrocytes suggesting no immune response to the AAV5 vector or therapeutic precursor sequences. These preclinical results suggest that using gene therapy to knock-down HTT may provide important therapeutic benefit for HD patients and raised no safety concerns, which supports our ongoing efforts for the development of an RNA interference-based gene therapy product for HD.

INTRODUCTION

Huntington’s disease (HD) is a fatal, currently untreatable, neurodegenerative disorder with a prevalence rate of 1–10 in 100,000 individuals worldwide. The presence of 40 and more CAG triplets in exon 1 of the huntingtin (HTT) gene has been identified as a fully penetrant trigger for the neuropathological process, which usually stretches over decades. The resultant neuronal death affects primarily GABAergic medium spiny neurons in the early stages. The CAG expansion is translated into a polyglutamine (polyQ) tract in the N-terminus of the HTT protein, causing the mutant HTT to misfold and aggregate. Growing evidence suggests that the mutant HTT disturbs multiple critical cellular pathways and that its aggregation is a prerequisite to neurodegeneration. Therefore, clearance of mutant HTT is currently accepted as being key for HD treatment. Notably, Yamamoto et al. showed that conditional blockage of HTT expression after symptom onset results in clearance of HTT aggregates and behavioral improvements, suggesting that HD may be partially reversible.

In contrast to other progressive neurodegenerative disorders, such as Alzheimer’s or Parkinson’s disease, the monogenic nature of HD allows for the development of disease-modifying therapies that aim to halt or suppress production of the aberrant HTT. The discovery of RNA interference (RNAi) in 1998 revolutionized the progress of therapeutic interventions focusing on gene silencing at the post-transcriptional level. Since then, several groups, including ours, applied RNAi principles to design artificial small interfering (si)RNAs, short hairpin (sh)RNAs or micro (mi)RNAs that bind to the HTT transcript and reduce its translation. To circumvent several challenges regarding the delivery and stable expression of RNAi products in the central nervous system, many studies have used viral vectors as delivery vehicles, which can be injected directly into the brain. reviewed in Kantor et al. Adeno-associated viral (AAV) vectors are the most common vehicles of choice and a large number of AAV capsid serotypes provide cell- and tissue- specific tropism. reviewed in Srivastava. For the central nervous system, studies in rodents and non human primates have shown AAV serotype 5 (AAVS) to be strong and effective in the brain, making it an attractive candidate for the RNAi-based gene transfer. Importantly, the AAV-delivered-miRNA-based gene therapy approach comprises continual expression of artificial miRNAs following a single administration of an AAV vector, resulting in long-term HTT lowering. To develop a disease-modifying gene therapy for HD, we have previously designed several therapeutic miRNAs targeting either both ‘total’ or preferentially the mutant HTT transcripts ‘allele-selective’ and their HTT knock-down efficiency was addressed in vitro and in the humanized transgenic Hu128/21

1Department of Research & Development, uniQure N.V., Amsterdam, The Netherlands; 2Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands; 3Neurosciences Research Center (CRN), Laboratory of Cellular and Molecular Neurotherapies (LCMN), Lausanne University Hospital, Lausanne, Switzerland and 4Department of Clinical Neurosciences, LCMN, Lausanne University Hospital, Lausanne, Switzerland. Correspondence: Dr P Konstantinova, Department of Research & Development, uniQure N.V., Paasheuvelweg 25A, 1105BP Amsterdam, The Netherlands.

E-mail: p.konstantinova@uniQure.com

Received 19 January 2017; revised 16 June 2017; accepted 25 July 2017; accepted article preview online 3 August 2017; advance online publication, 14 September 2017
HD mouse model. Based on this study, we selected a miHTT construct that showed the strongest efficacy in vitro and induces a potent total HTT knock-down in the striatum and cortex of the Hu128/21 HD mice. For the allele-selective HTT knock-down, we selected the miSNP50T and miSNP67T constructs that showed strongest efficacy in vitro.

Although several transgenic or knock-in HD animal models have been established and used for preclinical testing, none completely recapitulates the neuropathology that occurs in HD patients. Therefore, a combination of several in vivo preclinical studies is required to address the necessary treatment outcome and safety measures for HD before entering the clinic. In respect to the latter, the present study was designed to evaluate the on-target efficacy of continuously expressed miHTT, miSNP50T, and miSNP67T constructs in suppressing the neuropathology associated with HD using an acute lentiviral (LV) HD rat model. To generate the HD rat model, wild-type rats were injected intrastriatal ly with a LV vector expressing a chimeric mutant HTT fragment, which is shown to induce local formation of mutant HTT aggregates followed by severe neuronal dysfunction at two months post-infection. Therefore, this model allowed us to address the HD treatment response downstream of the mutant HTT protein in a larger rodent brain. Moreover, the chimeric LV sequence enabled us to study both total and allele-selective approaches in the context of mechanistic efficacy and gene specificity.

RESULTS
miHTT-155 delivered by an AAV5 vector suppressed mutant HTT aggregate formation and DARPP-32-associated neuronal dysfunction in HD rats
To assess distribution, mechanistic efficacy and allele selectivity of the therapeutic miRNA sequences, we initiated a pilot study in the acute LV HD rat model using the miHTT construct for the total HTT knock-down and the miSNP67T construct for the allele-selective knock-down. Both miHTT and miSNP67T constructs were previously designed in the engineered mmu-miR-155 precursor, named miHTT-155 and miSNP67T-155 (Figure 1a). The miHTT and miSNP67T expression cassettes also contained a sequence encoding green fluorescent protein (GFP) to assess transduction efficiency (Figure 1b).

We generated AAV5 viruses carrying the miHTT and miSNP67T expression cassettes and co-injected each virus bilaterally in the striatum (STR) of rats with LV-mtHTT-67C or LV-mtHTT-67T, and AAV5-miHTT-155 or AAV5-miSNP67T-155 vectors. The experimental groups and injection sites are outlined.

Figure 1. Design of a proof-of-concept study using the AAV5-miHTT-155 and AAV5-miSNP67T-155 vectors in an acute HD rat model. (a) The structure and sequence of the engineered mmu-pre-miR-155 precursor used in the study with the highlighted guide strand in pink. (b) Schematic representation of the AAV5-miHTT-155 and AAV5-miSNP67T-155 expression cassettes; and LV-mtHTT-67C and LV-mtHTT-67T expressing the chimeric mutant HTT sequences. (c) Bilateral co-injections in the striatum (STR) of rats with LV-mtHTT-67C or LV-mtHTT-67T, and AAV5-miHTT-155 or AAV5-miSNP67T-155 vectors. The experimental groups and injection sites are outlined.
more miHTT molecules in the AAV5-miHTT-155-injected rats compared with the saline control (Figure 2b).

The accumulation of mutant HTT aggregates in the brain is a hallmark of the HD neuropathological process. To validate on-target silencing efficacy of the AAV5-miHTT-155 and AAV5-miSNP67T-155 expression products, we performed IHC using an anti-HTT antibody that binds to the mutant HTT (Figure 2c). We observed significantly fewer mutant HTT aggregates in the HD rat striata injected with the AAV5-miHTT-155 (0.4 × 10^6 ± 0.2 × 10^6, P ≤ 0.0001) or AAV5-miSNP67T-155 viruses (0.8 × 10^6 ± 0.3 × 10^6, P ≤ 0.0001) compared with the saline control (2.4 × 10^6 ± 0.4 × 10^6) (Figure 2d). The AAV5-miSNP67T-155 showed no allele-selectivity as similarly low counts of mutant HTT aggregates were observed in both LV-mtHTT-67C (0.6 × 10^6 ± 0.2 × 10^6) and LV-mtHTT-67T-injected rats compared with the corresponding saline controls.

To address the effect of AAV5-miHTT-155 and AAV5-miSNP67T-155 treatments on HD-linked neuronal dysfunction, we stained for dopamine- and cyclic-AMP-regulated phosphoprotein of 32 kDa (DARPP-32), a phosphoprotein widely expressed in medium spiny neurons. Consistent with the low accumulation of mutant HTT aggregates, we observed a significant reduction of DARPP-32 lesion size two months after AAV5-miHTT-155 (0.19 mm^3 ± 0.11, P ≤ 0.0001) or AAV5-miSNP67T-155 (0.62 mm^3 ± 0.19, P ≤ 0.0001) treatments compared with the saline control (1.92 mm^3 ± 0.29) (Figures 2e and f). AAV5-miHTT-155 was again shown to be the most effective. Moreover, consistent with the...
mutant HTT aggregate counts, AAV5-miSNP67T-155 showed no allele selectivity as demonstrated by a similar DARPP-32 lesion size in both LV-mtHTT-67C (0.07 mm³ ± 0.07) and LV-mtHTT-67T-injected rats relative to the saline controls. These experiments enabled us to identify the miHTT guide sequence effectively targeting HTT, which resulted in a strong suppression of mutant HTT aggregate formation and neuronal dysfunction at two months post-injection.

Optimized miHTT-451 and miSNP50T-451 expressed from AAV5 vectors induced the mutant HTT mRNA knock-down in HD rats. Although the engineered mmu-miHTT-155 constructs generates the favorable miHTT effector sequence and is suitable for pilot experiments addressing efficacy and distribution, it is not optimal for clinical studies in humans due to a high risk of immune response to GFP and possibility of off-target silencing caused by the passenger strand.16 Previously, we showed that the silencing efficacy and processing of the miHTT construct are influenced by the pre-miHTT precursor.18 We identified the miHTT-451 precursor that showed no passenger strand in vivo opposite to the miHTT-101 and miHTT-135 precursors (Figure 3a). Moreover, the miHTT-451 construct showed efficacious HTT knock-down and no signs of toxicity. Therefore, in this study we included the miHTT-451 precursor for the total HTT knock-down. For the allele-selective approach, we optimized the miSNP50T construct designed to preferentially bind to HTT messenger RNA (mRNA) carrying the U isoform of SNP rs362331, which is associated at high frequencies with HD.25 This miSNP50T construct, which exhibits stronger efficacy than miSNP67T in vitro, was not available when the pilot study was initiated and therefore, it was introduced at this stage. Moreover, for both constructs the cytomegalovirus immediate-early enhancer fused to chicken δ promoter together with GFP was replaced by the strong allele-selective approach, we optimized the miSNP50T construct is suitable for pilot studies in humans due to a high risk of immune response to GFP and possibility of off-target silencing caused by the passenger strand.18 Previously, we showed that the silencing efficacy and processing of the miHTT construct are influenced by the pre-miHTT precursor.18 We identified the miHTT-451 precursor that showed no passenger strand in vivo opposite to the miHTT-101 and miHTT-135 precursors (Figure 3a). Moreover, the miHTT-451 construct showed efficacious HTT knock-down and no signs of toxicity. Therefore, in this study we included the miHTT-451 precursor for the total HTT knock-down. For the allele-selective approach, we optimized the miSNP50T construct designed to preferentially bind to HTT messenger RNA (mRNA) carrying the U isoform of SNP rs362331, which is associated at high frequencies with HD.25 This miSNP50T construct, which exhibits stronger efficacy than miSNP67T in vitro, was not available when the pilot study was initiated and therefore, it was introduced at this stage. Moreover, for both constructs the cytomegalovirus promoter together with GFP was replaced by the strong cytomegalovirus immediate-early enhancer fused to chicken β-actin (CAG) promoter, which has been shown to be effective in the brain.26 The resultant constructs are named miHTT-451 and miSNP50T-451 (Figure 3b).

To further establish mechanistic efficiency, safety, as well as allele selectivity in vivo, we generated AAV5-miHTT-451 and AAV5-miSNP50T-451 vectors and co-injected them bilaterally in the striatum of rats with a LV vector encoding a chimeric mutant HTT sequence with an 82Q chain and carrying target regions for the miHTT and miSNP50T constructs, named LV-mtHTT-50T (Figures 3b and c). In order to address the allele-selective potential of the miSNP50T construct, we included a second LV vector, named LV-mtHTT-50C. The AAV5-miSNP50T-451 expression product was designed to have one nucleotide mismatch with the LV-mtHTT-50T transcripts and two nucleotide mismatches with the LV-mtHTT-50C transcripts. Therefore, this system enabled us to test the allele selectivity based on only a single SNP. As negative controls, we included a GFP expressed from the CAG promoter and saline control. Two months post-injection, rats were euthanized and the brains were processed to assess on-target efficacy, HD-like neuronal dysfunction, and immune reaction.

To measure AAV5 vector DNA in striata, we performed real-time quantitative PCR (qPCR) with primers directed towards the CAG promoter (Figure 3d). We observed high and comparable vector DNA in the striatal homogenates from AAV5-GFP-, AAV5-miHTT-451- and AAV5-miSNP50T-451-injected rats. Similar to TaqMan assays (data not shown), we detected a background level of ~3000 genome copies in the saline control, which was considered for calculations of final vector DNA. Furthermore, the latter inversely correlated with the human-specific HTT mRNA knockdown from the same tissue homogenate demonstrated by TaqMan RT-qPCR (Figure 3e). We detected 62.3% ± 21.6 HTT mRNA knock-down in AAV5-miHTT-451- and 81% ± 4.3 HTT mRNA knock-down in AAV5-miSNP50T-451-injected rats as compared with the saline control. We observed similar HTT mRNA knock-down by AAV5-miSNP50T-451 in LV-mtHTT-50T-injected rats compared with LV-mtHTT-50C-injected rats where 65.5% ± 9.2 HTT mRNA reduction was detected.

On-target silencing efficiency of AAV5-miHTT-451 and AAV5-miSNP50T-451 correlates with suppression of DARPP-32-associated neuronal dysfunction in HD rats.

To establish the ability of our optimized AAV5-miHTT-451 and AAV5-miSNP50T-451 vectors to suppress formation of mutant HTT aggregates, we analyzed striato-cortical sections by IHC using an anti-HTT antibody (Figure 4a). Here, in the AAV5-miHTT-451-injected rats almost no detectable mutant HTT aggregates were observed (843 ± 359, P < 0.0001), whereas the aggregates were abundant in the GFP (3.6x10⁴ ± 2.9x10⁴) and saline controls (4.4x10⁴ ± 2x10⁴) controls (Figure 4b). Based on the number of mutant HTT aggregates, AAV5-miSNP50T-451 showed stronger silencing of the matched LV-mtHTT-50T expression product (1x10³ ± 0.8x10³, P < 0.001) compared with the mismatched LV-mtHTT-50C (4.5x10⁴ ± 2.6x10⁴), suggesting allele-selective potential.

During development of symptomatic HD, the appearance of mutant HTT aggregates precedes the death of medium spiny neurons located in the striatum.22 Therefore, we addressed the potential of our AAV5-miHTT-451 and AAV5-miSNP50T-451 vectors to suppress DARPP-32-associated neuronal dysfunction by performing IHC against DARPP-32 (Figures 4c and d). Consistent with lowering of mutant HTT aggregates, AAV5-miHTT-451 (0.02 mm³ ± 0.03, P < 0.0001) and AAV5-miSNP50T-451 (0.12 mm³ ± 0.04, P < 0.0001) treatments significantly suppressed the partial striatal lesion induced by the LV-mtHTT-SNP50T expression product compared with the GFP (0.92 mm³ ± 0.39) and saline controls (1.09 mm³ ± 0.31). In contrast, AAV5-miSNP50T-451 treatment did not show strong reduction in the size of DARPP-32 lesions in LV-mtHTT-SNP50C-injected rats (0.96 mm³ ± 0.29), demonstrating allele selectivity.

AAV5 viruses delivering the miHTT-451 or miSNP50T-451 precursors did not induce an overt immune response via GFAP and Iba1 activation.

Although AAV-based gene therapy is an attractive approach for the delivery of gene products, such as therapeutic miRNAs, and overall has demonstrated low toxicity to date, activation of the immune response should be addressed for each therapeutic candidate in a given target tissue. To evaluate the immune response to our AAV vectors expressing therapeutic miRNA precursors in the brain, we analyzed the activation of microglia and infiltration of astrocytes in the injected areas by IHC using an anti-ionized calcium-binding adapter molecule 1 (Iba1) and anti-glia fibrillary acidic protein (GFAP) antibody, respectively (Figures 5a and b). We found similar levels of immunoreactivity in AAV5-miHTT-451- and AAV5-miSNP50T-451-treated rats compared to the saline control, indicating no apparent activation of immune reaction via microglia and astrocytes.

AAV5-miHTT-451 and miSNP50T-451 constructs do not generate a passenger strand in vivo.

Previously, we showed that the miHTT-451 construct does not generate a passenger strand and is not toxic probably due to higher specificity in vivo (Figure 6a).18 The absence of the passenger strand from the miR-451 scaffold provides a better safety profile for therapeutic shRNAs or miRNAs since it reduces the chance for off-target suppression of other genes by the passenger strand.18,27,28 To establish the absence of a passenger strand for the miSNP50T-451 construct in vivo, we analyzed the processing patterns in the striatum of AAV5-miSNP50T-451-injected rats by next-generation sequencing. We observed
consistent processing patterns between the analyzed samples (Figure 6b). The most abundant reads were 23 nucleotides long and belonged to the miSNP50T guide strand (Figure 6c). We did not observe any reads belonging to the passenger strand, confirming the absence of a passenger strand associated with the miR-451 precursor.

Based on this study, we identify the AAV5-miHTT-451 construct as the most efficient candidate for the gene therapy approach targeting HTT by showing a robust suppression of crucial HD pathological features in the rat model of HD.

**DISCUSSION**

In the current study, we have demonstrated the feasibility of total and allele-selective HTT silencing induced by therapeutic miRNAs delivered to the brain. Intracerebral administration of AAV5 vectors delivering the miHTT candidates for total HTT knockdown or the miSNP50T and miSNP67T candidates for the allele-selective approach resulted in suppression of mutant HTT aggregates and prevention of DARPP-32-associated neuronal dysfunction in rat striata. The AAV5-miHTT-451 construct recapitulated the *in vitro* observations by demonstrating the strongest efficacy *in vivo*.

The LV HD rat model very closely and rapidly reproduces the critical pathogenic features of HD: the mutant HTT aggregation and striatal neuronal dysfunction. Although this model does not permit study of improvement in HD-like behavioral symptoms, it provides a means to preselect therapeutic candidates to continue with high-cost preclinical studies in large animals that carry on for several months to years. Previous studies with shRNAs showed equivalent silencing efficacy of the chimeric HTT constructs in rats and HEK-293T cells compared with silencing of the endogenous full-length human HTT in HD-derived neuronal cultures, suggesting that accessibility of silencing agents to the chimeric HTT constructs resembles the natural situation. Moreover, the rapid severity of DARPP-32-associated neuronal dysfunction challenges the read-out efficacy; but on the other hand, it strengthens confidence in case efficacy is demonstrated.
Most HD patients are heterozygous at the HTT locus and therefore many studies attempt to target only the mutant HTT. However, the nature of the HD mutation makes allele-selective HTT silencing challenging. To distinguish between the mutant and healthy HTT alleles, most of the therapeutic interventions so far have focused on targeting the heterozygous HD-associated SNPs or CAG expansions. However, not all HD patients have the identified common SNP isoforms linked to HD. Therefore, more than one product would be needed to fully address the HD patient population. For instance, one study showed that five therapeutic products targeting the isoforms of three different SNPs are required to treat three-quarters of the United States and European HD patient populations. Moreover, as a personalized medicine, additional genotyping will be required to identify suitable HD candidates for a given clinical trial. Furthermore, the allele selectivity based on targeting the CAG expansions depends on a difference between the consecutive CAGs located on the mutant and healthy HTT alleles. Nevertheless, it has not shown to be more efficacious than the SNP approach, when simultaneously tested. Ultimately, the presence of CAG repeats in more than 66 genes increases the chance for off-targeting, making it a less attractive target for clinical testing. Consequently, the allele-selective approach still faces obstacles to advance into the clinical development.

In this study, we identified AAV5-miSNP50T-451 that showed allele-selective silencing of the HTT allele carrying the T isoform of SNP rs362331. The ongoing experiments with the Hu128/21 mice that express full-length human HTT with the U isoform of SNP rs362331 will provide more insights into efficacy and allele-selectivity of the AAV5-miSNP50T-451. The AAV5-miSNP67T-155 construct showed no allele-selectivity in vivo. mfold prediction analysis indicated that the secondary RNA structures of miHTT, miSNP67T and miSNP50T target sites do not form stable duplexes (data not shown), supporting their similar accessibility to the therapeutics. Previously, it has been reported that allele-selective potential of artificial miRNAs observed in vitro may not be retained in vivo. In general, miRNA–mRNA interactions are determined by the sequence composition that influences the thermodynamics, such as the melting temperature, of the duplex RNA. miSNP67T binds to 52%-rich GC region, which could enhance the miRNA: mRNA pairing stability and ultimately contribute to no allele-selectivity based on a single SNP observed in vivo.

Most HTT lowering strategies intend to suppress both HTT alleles and the first ongoing clinical trial with antisense oligonucleotides...
employs this approach (https://clinicaltrials.gov/). Preclinical studies using HD animal models and non-human primates indicate that there is a therapeutic window where total HTT knock-down is safe and yet beneficial for HD patients. Importantly, this strategy would provide a treatment for all HD patients independent from their genotype. In this study, we showed that the miHTT construct processed from the miR-451 scaffold is able to strongly suppress mutant HTT aggregation and ultimately dramatically reduce the generation of striatal lesions at two months post-injection. Moreover, we did not observe immune reaction to the AAV5-miHTT-451 vector via astrocytes or microglia activation, suggesting a favorable safety profile.

Altogether, these data provide strong evidence for the therapeutic efficacy of the AAV5-miHTT-451 vector by inducing functional improvements downstream in the HD pathological process without raising safety concerns in a rodent model of HD. These promising results support our ongoing efforts for the development of an HD-modifying treatment by silencing the human HTT gene.

MATERIALS AND METHODS

HTT target sequences
Homo sapiens HTT mRNA, complete CDS (gb|L12392.1|HUMHDA) obtained from http://blast.ncbi.nlm.nih.gov/Blast.cgi, was used to identify target sequences for the artificial miHTT targeting exon 1, the miSNP50 construct binding to the U isoform of SNP rs362331, and the miSNP67 construct targeting the U isoform of SNP rs362307.

DNA constructs
To generate the miHTT-155 and miSNP67T-155 constructs, their guide and passenger strand sequences were incorporated in the hsa-pri-miR-451a scaffold. 200 nucleotides long 5’ and 3’ encompassing flanking regions were included with EcoRV and BamHI restriction sites and the complete sequences were ordered from GeneArt gene synthesis (Invitrogen).
these constructs, the cytomegalovirus promoter was replaced by the CAG promoter (Inovio, Plymouth Meeting, PA).40

AAVs vector production

AAVs vectors expressing mHTT, miSNP50T, miSNP67T and GFP were produced by baculovirus-based AAV production system (uniQure, Amsterdam, The Netherlands). The artificial miRNA cassettes were cloned in a transfer plasmid in order to generate an entry plasmid. The expression cassettes were inserted in a recombinant baculovirus vector by homologous recombination and clones were selected by plaque purification. The recombinant baculovirus containing the cassettes were further amplified till the passage 6 and clones screened for the best production and stability by PCR and qPCR. To generate AAVs, infections with different recombinant baculoviruses containing the vector genome, the replicon enzyme and the capsid protein were performed. The cells were lysed 72 h after infection and the crude lysate was treated with Benzonase (50 U ml\(^{-1}\); Merck, Darmstadt, Germany) for 1 h at 37 °C. AAVs was purified on AVB Sepharose column (GE Healthcare, Little Chalfont, UK) using AKTA Explorer purification system (GE Healthcare) and the genome copy titer was determined by qPCR.

Lentiviral vector production

LVs were produced in HEK-293T cells with the four-plasmid system, as previously described.40 Human immunodeficiency virus type-1 vectors were pseudotyped with the vesicular stomatitis virus glycoprotein envelope, concentrated by ultra centrifugation and resuspended in phosphate-buffered saline (PBS, Gibco, Life Technologies, Zug, Switzerland) supplemented with 1% bovine serum albumin (BSA, Sigma-Aldrich, Buchs, Switzerland). The viral particle content of each batch was determined by p24 antigen enzyme-linked immunosorbent assay (p24 ELISA, RETROtek, Kampenhout, Belgium). Viral stocks were stored at −80 °C. Lentiviral vectors encoding the mutant HTT fragments were used at 300 ng of p24. Based on transcriptional start site from the PGK promoter −dially perfused at a rate of 20 ml min\(^{-1}\) with 300 ml of 4% PFA. Brains were removed and post-fixed by incubation in 4% PFA for 24 h at 4 °C and cryoprotected by incubation in 20% sucrose (Sigma-Aldrich, Buchs, Switzerland) in 1x PBS for 24 h and in 30% sucrose in 1x PBS for 24 h. Brains were frozen on dry ice and then stored at −80 °C. For RNA analysis, the animals were euthanized and the brains were snap-frozen in liquid nitrogen.

25 μm-thick coronal brain sections were cut on a sledge microtome with a freezing stage at ~30 °C (Leica SM2010R, Biosystems Switzerland, Nunningen, Switzerland). Sections throughout the striatum were collected and kept in tubes, as free-floating sections in a quenching solution (25% glycerol (Sigma-Aldrich, Buchs, Switzerland), 30% Ethylene glycol (Merck, Nottingham, UK), 25% 1x PBS and 20% nanopure water).

Immunostaining

Free-floating sections were washed three times, for 10 min each, in Tris-buffered saline (TBS, 10 mM Tris pH = 7.6 and 0.9% NaCl Sigma-Aldrich, Buchs, Switzerland). Non-specific peroxidases were inactivated by incubation in solution (TBS supplemented with 3% H\(_2\)O\(_2\) and 10% methanol, Sigma-Aldrich, Buchs, Switzerland) for 15 min at room temperature. Sections were washed twice, for 10 min each, in TBS, and then for 10 min in TBS-0.1% Triton X-100 (TBST). Sections were blocked by incubation in Tris-high salt-buffer (THST, 50 mM Tris pH = 7.6, 0.5 M NaCl, 0.5% Triton X-100,) for anti-HTT antibody or TBST-5% NGS for DARPP-32 antibody during 1 h at room temperature and were then incubated overnight at 4 °C in TBST-1% BSA with antibodies. The following primary antibodies were used: Goat polyclonal anti-HTT antibody (1/1000, Sigcen, Coimbra, Portugal), rabbit polyclonal anti-DARPP-32 antibody (1/1000, Cell Signaling Technology Europe, Leiden, The Netherlands), rabbit polyclonal anti-GFP antibody (1/1000, Abcam, Cambridge, UK), rabbit polyclonal anti-β-actin antibody (1/25 000, Wako Chemicals, Richmond, USA) and rabbit polyclonal anti-GFAP antibody (1/500, Dako, Baar, Switzerland). After incubation with the primary antibody, the sections were washed three times, for 10 min each, in TBS and then incubated for 1 h at room temperature in TBST-1% BSA with secondary antibodies. The following secondary antibodies were used: biotinylated donkey anti-goat IgG (1/1000, Jackson, Pennsylvania, USA) and biotinylated goat anti-rabbit IgG (1/400, Vector Lab Inc, Burlingame, USA). Sections were washed three times, for 10 min each, in TBS and incubated for 1 h at RT in ABC (Vector Lab Inc). Samples were washed twice, for 10 min each, in TBS and then incubated with nickel chloride and diamino benzidine (DAB, SIGMA, UK) for 1 h at RT in ABC. Sections were dehydrated (100% ethanol in nanopure water, 95% ethanol in nanopure water, 100% ethanol, 100% ethanol and xylene) before mounting in Eukitt (Kindler GmbH, Freiburg, Germany).

Image acquisition and quantification

Images were obtained with a digital camera (3CCD Hitachi HV-F2025CL) on a slide scanner microscope (×20 objective, Zeiss axiostar Z1). Measurements were made with Image J software (http://rsb.info.nih.gov/ij/). Images were acquired with a freezing stage at 30 °C (Leica SM2010R, Biosystems Switzerland, Nunningen, Switzerland). Sections throughout the striatum were collected and kept in tubes, as free-floating sections in a quenching solution (25% glycerol (Sigma-Aldrich, Buchs, Switzerland), 30% Ethylene glycol (Merck, Nottingham, UK), 25% 1x PBS and 20% nanopure water).

Quantification of mHTT aggregates and DARPP-32 lesions

The number of mutant HTT aggregates in the striatum was automatically counted in 1 in 8 sections with analyze particle plugin on Image (Scion Image, NIH, Bethesda, USA) for aggregates and Zeiss Zen Lite 2 (blue Edition; Carl Zeiss AG, Germany) for DARPP32 lesion. An Image J macro was developed to count the number of aggregates. The aggregates were identified on the basis of their intensity relative to the background, their size and their circularity. The same intensity, size and circularity parameters were used for all samples.

Quantitative real-time PCR

Rat striata were crushed using CryoPrep System (Covaris, Woburn, MA, USA) and the powder was divided for RNA and DNA analyses. For RNA
isolation, the striatal powder was homogenized in Trizol using gentleMACS Dissociator (Miltenyi Biotec) and total RNA was isolated from Trizol according to the manufacturer’s protocol (Invitrogen). To remove genomic DNA, RNA was treated with dsDNase (Thermo Scientific, Waltham, MA, USA). Quantitative real-time PCR reaction was performed to detect HTT mRNA knock-down using TaqMan gene expression assays (Applied Biosystems, Foster City, CA, USA), human HTT (Hs00918134_m1), rat GAPDH (Rn01426626_g1); and miHTT expression levels using custom TaqMan microRNA expression assay or U6 snRNA (001973; Applied Biosystems). The expression level of each gene was normalized to either endogenous GAPDH or U6 snRNA levels. Fold change/percentages of reads to the reference sequences of the pre-miHTT and pre-miSNP50T constructs (Qiagen). All reads containing ambiguity N symbols, reads shorter than 10

RNA raw data sets were analyzed using the CLC Genomics Workbench 6 calculated.

Next-generation sequencing data analysis

The raw sequencing data were produced as previously described.18 Small RNA raw data sets were analyzed using the CLC Genomics Workbench 6 (Qiagen). All reads containing ambiguity N symbols, reads shorter than 10 nucleotides, longer than 45 nucleotides and reads represented less than 10 times were discarded. The obtained unique small RNA reads were aligned to the reference sequences of the pre-miHTT and pre-miSNP50T constructs with a max. of 3 nucleotide mismatches allowed. The percentages of reads based on the total number of reads matching the reference sequences were calculated.

Sample sizes, calculations and statistical analysis

Sample sizes of saline n = 18, GFP n = 16, AAVs-miHTT-155 n = 18, AAVs-miHTT-451 n = 16, AAVs-miSNP67T-155 n = 16 and AAVs-miSNP50T-451 n = 16 represent the number of striata injected per experimental group. The sample size was chosen to consider statistical variability due to surgical procedure based on previous studies. All experiments involving animals were performed once. The only exclusion criterion was if a problem was encountered during the injection procedure. The knock-down percentages were calculated using the following formula: Knock-down (%) = [AAVS-miRNA treatment]/[saline treatment] × 100%. Data were analyzed using one-way ANOVA. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. Differences were considered significant when P<0.05. The values were calculated as a mean ± s.d.

CONFLICT OF INTEREST

JMI, RM, CCB, JL, MME, HP and PK are employees and shareholders at uniQure. ND and CHUV have a collaborative agreement with uniQure. uniQure has sponsored a portion of the research performed in ND lab.

ACKNOWLEDGEMENTS

We thank Dr Eileen Sawyer and Dr Olivier ter Brake for critically reviewing the manuscript.

REFERENCES

1 Rawlins MD, Wexler NS, Wexler AR, Tabrizi SJ, Douglas I, Evans SJW et al. The prevalence of Huntington’s disease. Neuroepidemiology 2016; 46: 144–153.

2 Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR. A new model for prediction of the age of onset and penetrance for Huntington’s disease based on CAG length. Clin Genet 2004; 65: 267–277.

3 The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 1993; 72: 971–983.

4 Ross CA, Tabrizi SJ. Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011; 10: 83–98.

5 Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR et al. Huntington disease. Nat Rev Dis Primers 2015; 1: 15005.

6 DiFiliga M, Sapp E, Chase KD, Davies SW, Bates GP, Vonsattel JP et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997; 277: 1990–1993.

7 Ross CA, Aylward EH, Wild ED, Langbehn DR, Long JD, Warner JH et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 2014; 10: 204–216.

8 Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington’s disease. Cell 2000; 101: 57–66.

9 Fire A, Xu S, Montgomery MK, Costas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806–811.

10 Boudreau RL, Rodriguez-Lebron E, Davidson BL. RNAi for the brain: progresses and challenges. Hum Mol Genet 2011; 20: 21–27.

11 Aronin N, DiFiliga M. Huntington-lowering strategies in Huntington’s disease: antisense oligonucleotides, small RNAs, and gene editing. Mov Disord 2014; 29: 1455–1461.

12 Kantor B, Bailey RM, Wimbbery K, Kalburgi SN, Gray SJ. Methods For Gene Transfer To The Central Nervous System. Adv Genet 2014; 87: 125–197.

13 Srivastava A. In vivo tissue-tropism of adeno-associated viral vectors. Curr Opin Virol 2016; 21: 75–80.

14 Markakis EA, Vives KP, Bober J, Leichtle S, Lenarth C, Beecham J et al. Comparative transduction efficiency of AAV vector serotypes 1–6 in the substantia nigra and striatum of the primate brain. Mol Ther 2010; 18: 588–593.

15 Burger C, Gorbatyuk OS, Velardo MJ, Peden CS, Williams P, Zolotukhin S et al. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 2004; 10: 302–317.

16 Lin D, Fantz CR, Levy B, Rafi MA, Vogler C, Wenger DA et al. AVAV/5 vector expressing galactocerebroside ameliorates CNS disease in the murine model of globoid-cell leukodystrophy more efficiently than AAV2. Mol Ther 2005; 12: 422–430.

17 Samaranch L, Blits B, San Sebastian W, Hadaczek P, Braggs J, Sudhakar V et al. MR-guided parenchymal delivery of adeno-associated viral vector serotype 5 in non-human primate brain. Gene Ther 2017; 24: 253–261.

18 Miniarikova J, Zanella I, Huseinovic A, van der Zon T, Hanemaaijer E, Martir R et al. Design, characterization, and lead selection of therapeutic miRNAs targeting huntingtin for development of gene therapy for Huntington’s disease. Mol Ther Nucleic Acids 2016; 5: e297.

19 Menalled L, Brunner D. Animal models of Huntington’s disease for translation to the clinic: best practices. Mov Disord 2014; 29: 1375–1390.

20 Ramaswamy S, McBride JL, Kordower JH. Animal models of Huntington’s disease. ILAR J 2007; 48: 355–373.

21 Poula Di, Morton AJ, Hayden MR. Choosing an animal model for the study of Huntington’s disease. Nat Rev Neurosci 2013; 14: 708–721.

22 de Almeida LP, Ross CA, Zala D, Aebischer P, Deglon N. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathy pathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J Neurosci 2002; 22: 3473–3483.

23 Drouet V, Ruiz M, Zala D, Feyeux M, Auregan M, Cambon K et al. Allele-specific silencing of mutant huntingtin in rodent brain and human stem cells. PloS ONE 2014; 9: e99341.

24 Omeri CT, Langley-Gullion KC, Greengard P. Quantitative immunocytochemistry of DARPP-32-expressing neurons in the rat caudateputamen. Brain Res 1998; 808: 8–12.

25 Lombardi MS, Saspers L, Spronkmans C, Gellera C, Taroni F, Di Maria E et al. A majority of Huntington’s disease patients may be treatable by individualized allele-specific RNA interference. Exp Neurool 2009; 217: 312–319.

26 Klein RL, Hamby ME, Gong Y, Hinko AC, Wang S, Hughes JA et al. Dose and promoter effects of adeno-associated viral vector for green fluorescent protein expression in the rat brain. Exp Neurol 2002; 176: 66–74.

27 Ma H, Zhang J, Wu H. Designing Ago2-specific siRNA/shRNA to avoid competition with endogenous miRNAs. Mol Ther Nucleic Acids 2014; 3: e176.

28 Herrera-Carrillo J, Harwig A, Liu YP, Berkhout B. Probing the siRNA characteristics that hinder Dicer recognition and consequently allow Ago-mediated processing and AgosRNA activity. RNA 2014; 20: 1410–1418.

29 Yu D, Pendergraft H, Liu J, Kordasiewicz HB, Cleveland DW, Swazy EE et al. Single-stranded RNAi uses RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell 2012; 150: 895–908.

30 Carroll JB, Barby SC, Southwell AL, Doty CN, Greenlee S, Skotte N et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene/allele-specific silencing of mutant huntingtin. Mol Ther 2011; 19: 2178–2185.

31 Pfister EL, Kennington L, Straubhaar J, Waghi S, Liu W, DiFiliga M et al. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington’s disease patients. Curr Biol 2009; 19: 774–778.

Gene Therapy (2017) 630–639
32 Kay C, Skotte NH, Southwell AL, Hayden MR. Personalized gene silencing therapeutics for Huntington disease. Clin Genet 2014; 86: 29–36.
33 Warby SC, Montpetit A, Hayden AR, Carroll JB, Butland SL, Visscher H et al. CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. Am J Hum Genet 2009; 84: 351–366.
34 Butland SL, Devon RS, Huang Y, Mead C-L, Meynert AM, Neal SJ et al. CAG-encoded polyglutamine length polymorphism in the human genome. BMC Genomics 2007; 8: 126.
35 Monteys AM, Wilson MJ, Boudreau RL, Spengler RM, Davidson BL. Artificial miRNAs targeting mutant huntingtin show preferential silencing in vitro and in vivo. Mol Ther Nucleic Acids 2015; 4: e234.
36 Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 136: 215–233.
37 Stiles DK, Zhang Z, Ge P, Nelson B, Grondin R, Ai Y et al. Widespread suppression of huntingtin with convection-enhanced delivery of siRNA. Exp Neurol 2012; 233: 463–471.
38 McBride JL, Pitzer MR, Boudreau RL, Dufour B, Hobbs T, Ojeda SR et al. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington’s disease. Mol Ther 2011; 19: 2152–2162.

39 Grondin R, Kaytor MD, Ai Y, Nelson PT, Thakker DR, Heisel J et al. Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain 2012; 135: 1197–1209.
40 Hottinger AF, Azzouz M, Déglon N, Aebischer P, Zurn AD. Complete and long-term rescue of lesioned adult motoneurons by lentiviral-mediated expression of glial cell line-derived neurotrophic factor in the facial nucleus. J Neurosci 2000; 20: 5587–5593.
41 Adra CN, Boer PH, McBurney MW. Cloning and expression of the mouse pgk-1 gene and the nucleotide sequence of its promoter. Gene 1987; 60: 65–74.

Supplementary Information accompanies this paper on Gene Therapy website (http://www.nature.com/gt).